SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Gorilla and King Portfolio Candidates
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: rushnomore who wrote (49082)11/24/2001 6:41:27 PM
From: Cosmo Daisey  Read Replies (1) of 54805
 
Chiron Corporation (CHIR) Announces Results Of Phase III Study Of Tifacogin In Severe Sepsis; Chiron Says Sepsis Drug Fails To Meet Primary Goal; CHIR Stock Is Down -8.98% On Wednesday At Market Close

This is what i'm talkin about. VRTX qualifies as a gorilla candidate because they could have knocked out this drug candidate in phase one or even earlier in the design stage.
Phase three means CHIR has already spent about two $billion on Tifacogin. VRTX can do two years of wet lab research in 24 hours insilico.
Phase one is the place to knock out drug candidates before billions have been spent.
cdaiseyPhD@cheap-research.com
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News